Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDH-115
- Development stage
- Unknown
- Lead developer
- MD Healthcare
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
MDH-115 is a microbial extracellular vesicle (EV) nanotherapeutic being developed by MD Healthcare for the treatment of retinal diseases, including dry and wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). The drug utilizes MD Healthcare's proprietary platform technology, which leverages extracellular vesicles derived from microorganisms to deliver therapeutic effects. These microbial EVs are designed to modulate biological pathways involved in inflammation and angiogenesis, which are key drivers of retinal degeneration. As of late 2024, MDH-115 is in Phase 1/2 development, with Phase 1 clinical trials initiated in the fourth quarter of 2024 and Phase 2 trials projected for late 2027.
02
Targets
MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on MDH-115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDH-115.